SARMs and “Cutting”: What the Research Actually Supports
Online lists that rank the “best SARMs for cutting” usually convert cell, animal, or disease-specific findings into consumer performance claims. That leap is not supported by good human evidence. It is especially misleading when Cardarine (GW-501516) and SR9009 are grouped with SARMs even though neither compound is a selective androgen receptor modulator.
This article replaces a previous ranking with an evidence audit. It does not provide a stack, dose, cycle, or recommendation for human use.
Bottom line
- No SARM is authorized by Health Canada for fat loss, cutting, bodybuilding, or athletic performance.
- RAD-140 human research has focused on metastatic breast cancer, not body-composition cutting protocols.
- GW-501516 is a PPAR-delta agonist, not a SARM. Health Canada has identified unauthorized workout products labelled with GW-1516 and seized products combining GW-1516 with SR-9009.
- SR9009 is an experimental research ligand studied mainly in cells and animals. Published preclinical findings do not establish human efficacy or safety.
- Changes in an animal metabolic marker cannot establish meaningful fat-loss outcomes, safety, or an appropriate human exposure.
Start with correct compound classification
| Compound | Research class | What the cited evidence actually studies |
|---|---|---|
| RAD-140 (testolone/vosilasarm) | Selective androgen receptor modulator | A small first-in-human oncology trial evaluated safety, pharmacokinetics, and target engagement in postmenopausal patients with metastatic breast cancer. It was not a cutting study. |
| Ostarine (MK-2866/enobosarm) | Selective androgen receptor modulator | Clinical development has examined body composition and function in selected medical populations. Those endpoints do not authorize recreational physique claims. |
| GW-501516 (Cardarine) | PPAR-delta agonist | Mechanistic, animal, and limited clinical-development research on lipid and metabolic pathways. It is not a SARM. |
| SR9009 (Stenabolic) | Experimental REV-ERB-associated research ligand | Predominantly cell and animal studies. Research also reports effects that may be independent of REV-ERB, adding uncertainty about mechanism. |
Why the earlier ranking was not defensible
The previous version described compounds as if they were established tools for fat loss, endurance, muscle preservation, and stacking. Its references did not support those conclusions:
- The cited RAD-140 paper involved 22 patients with metastatic breast cancer. It cannot establish outcomes or tolerability in healthy people pursuing a calorie deficit.
- The cited GW-501516 literature examined molecular and metabolic endpoints. A pathway effect is not equivalent to a proven or safe body-fat outcome.
- The cited SR9009 work was preclinical. Cell and mouse results cannot be translated directly into a human protocol.
- No cited study tested the promoted multi-compound stack, so the interaction claim had no evidentiary basis.
What Health Canada currently says
Health Canada states that SARMs have not been authorized in Canada for any medical use and associates them with serious concerns including hormonal suppression and heart or liver disease. Its guidance also notes that products promoted as SARMs may contain another drug or an undeclared ingredient.
In a July 2025 safety alert, Health Canada listed unauthorized workout products labelled with GW-1516 and a GW-1516/SR-9009 combination. The agency advises consumers to stop using listed unauthorized products and explains that unauthorized products have not been assessed for safety, effectiveness, or quality.
For competitive sport, the World Anti-Doping Agency’s 2026 Prohibited List is the authoritative starting point. A compound’s appearance in laboratory research does not make it permitted in sport or approved for personal use.
How preclinical evidence should be read
Preclinical models are valuable for identifying mechanisms and deciding what to study next. They are not a substitute for human evidence. Translation can fail because of species differences, exposure, bioavailability, study duration, selected endpoints, or off-target activity.
SR9009 illustrates the problem. It is often described online only as a REV-ERB agonist, yet published work has reported REV-ERB-independent effects on cell proliferation and metabolism. That does not make the compound useless as a research tool; it means broad consumer claims based on a single proposed mechanism are too confident.
Research-quality questions that matter
- Was the compound identity confirmed by an appropriate analytical method?
- Does the COA identify the lot, method, date, result, and testing laboratory?
- Is the study in cells, animals, patients, or healthy volunteers?
- Was the outcome a mechanistic marker, body composition, performance, or a validated clinical endpoint?
- Were adverse events, laboratory changes, withdrawals, and follow-up reported?
- Does the claim match the actual compound and study population?
Use our COA and testing documentation guide to assess analytical records, and consult the Complete SARMs Research Guide for compound-by-compound evidence boundaries.
References
- Health Canada: Using bodybuilding products.
- Health Canada: Unauthorized workout supplements safety alert.
- First-in-human phase 1 study of RAD-140 in metastatic breast cancer.
- SR9009 has REV-ERB-independent effects on cell proliferation and metabolism.
- World Anti-Doping Agency: 2026 Prohibited List.
Research and regulatory information only. This article does not recommend human use and is not medical advice.